PROCEPT BioRobotics (PRCT) Expected to Announce Earnings on Wednesday
by Amy Steele · The Cerbat GemPROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.5528) per share and revenue of $80.6530 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The business had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter last year, the firm posted ($0.35) EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
PROCEPT BioRobotics Stock Performance
Shares of PRCT stock opened at $24.36 on Monday. PROCEPT BioRobotics has a 12 month low of $19.35 and a 12 month high of $66.85. The stock has a market cap of $1.39 billion, a PE ratio of -14.25 and a beta of 0.94. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The company’s fifty day moving average price is $25.53 and its 200-day moving average price is $29.76.
Analyst Upgrades and Downgrades
PRCT has been the topic of a number of analyst reports. Robert W. Baird initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, March 6th. They issued a “neutral” rating and a $30.00 price target on the stock. Jefferies Financial Group cut shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 26th. Bank of America cut shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $38.00 to $20.00 in a research note on Thursday, February 26th. Piper Sandler dropped their price target on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Finally, Wells Fargo & Company dropped their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $40.82.
Check Out Our Latest Stock Analysis on PROCEPT BioRobotics
Insider Buying and Selling
In other PROCEPT BioRobotics news, EVP Kevin Waters sold 6,721 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total transaction of $159,287.70. Following the transaction, the executive vice president owned 152,264 shares in the company, valued at approximately $3,608,656.80. This represents a 4.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Antal Rohit Desai bought 167,246 shares of the stock in a transaction on Thursday, March 5th. The shares were bought at an average price of $25.58 per share, for a total transaction of $4,278,152.68. Following the purchase, the director directly owned 167,246 shares in the company, valued at approximately $4,278,152.68. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. 17.40% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On PROCEPT BioRobotics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd lifted its stake in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the period. US Bancorp DE lifted its stake in PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after acquiring an additional 1,079 shares during the period. Kestra Advisory Services LLC bought a new position in PROCEPT BioRobotics during the 4th quarter valued at about $68,000. Lazard Asset Management LLC lifted its stake in PROCEPT BioRobotics by 90.7% during the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after acquiring an additional 810 shares during the period. Finally, Osaic Holdings Inc. lifted its stake in PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after acquiring an additional 337 shares during the period. Institutional investors own 89.46% of the company’s stock.
About PROCEPT BioRobotics
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.